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Abstract: All laboratory tests have test performance character-
istics (TPCs), whether or not they are explicitly known to the
laboratorian or the pathologist. TPCs are thus also an integral
characteristic of immunohistochemistry (IHC) tests and other
in situ, cell-based molecular assays such as DNA or RNA in situ
hybridization or aptamer-based testing. Because of their de-
scriptive, in situ, cell-based nature, IHC tests have a limited
repertoire of appropriate TPCs. Although only a few TPCs are
relevant to IHC, proper selection of informative TPCs is
nonetheless essential for the development of and adherence to
appropriate quality assurance measures in the IHC laboratory.
This paper describes the TPCs that are relevant to IHC testing
and emphasizes the role of TPCs in the validation of IHC tests.
This is part 2 of the 4-part series “Evolution of Quality Assur-
ance for Clinical Immunohistochemistry in the Era of Precision
Medicine.”
Key Words: biomarkers, quality assurance, quality control,
validation, immunohistochemistry, test performance character-
istics
(Appl Immunohistochem Mol Morphol 2017;25:79–85)
H istorically, immunohistochemistry (IHC) has for allpractical purposes been considered a “special stain”
similar to traditional histochemical preparations; how-
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ever, it is more accurately described as a “cell-based in situ
immunoassay” and resides ﬁrmly within a class of on-
slide, in situ molecular tests that use one of a number of
diﬀerent probes (antibodies, RNAs, DNAs, aptamers or
other synthetic molecules) and enable the identiﬁcation of
speciﬁc complementary molecular targets.1 Unlike histo-
chemical tests, “on-slide molecular tests” use reagents that
have high (or very high) sensitivity and speciﬁcity (in the
nanomolar range) for individual targets.2–5 The great
majority of in situ tests, including IHC tests, are developed
in the individual laboratory and as such, they are best
designated as “laboratory developed tests” (LDTs).6 Ap-
plication of appropriate quality assurance measures and
the proper validation of “in situ cell-based molecular
tests” require a full understanding of which test perfor-
mance characteristics (TPCs) apply and how validation of
these tests is deﬁned. In addition, it is necessary to adapt
speciﬁc terminology relating to both quality assurance and
validation that was initially developed for liquid-based
assays. TPCs are essential for the characterization of
LDTs.7–11 As we will show, TPCs as a group are an in-
herent component of LDT validation.
In this paper, we will deﬁne the TPCs that are rel-
evant to in situ cell-based assays that have descriptive
readouts primarily generated by human readers (ie,
pathologists) ±assistive image analysis and will describe
the role of TPCs in the validation of the IHC test. This
work builds upon recently published recommendations
and guidelines for the validation of antibodies, and mo-
lecular and IHC assays from the College of American
Pathologists, recommendations for the standardization of
controls from the Ad Hoc International Expert Com-
mittee, as well as research applications of biomarkers in
preclinical and clinical trials for novel and emerging an-
ticancer drugs.12–19
TPCs FOR IN SITU CELL-BASED ASSAYS
Here, we adopt and deﬁne the following TPCs for
IHC: (1) sensitivity and speciﬁcity, (2) reproducibility and
robustness, (3) accuracy and precision, and (4) reportable
range (Table 1).
Sensitivity and Specificity
An Ad Hoc Committee recently published a pro-
posal for a new classiﬁcation of sensitivity and speciﬁcity
in IHC testing.17 The new concept, for the ﬁrst time, al-
lowed for observation of analytical sensitivity and speci-
ﬁcity in a descriptive, nonlinear method such as IHC. The
introduction of the concept of analytical sensitivity and
speciﬁcity for descriptive tests, and its distinction from
diagnostic sensitivity and speciﬁcity, and clinical sensi-
tivity and speciﬁcity, resulted in a 3-tier classiﬁcation of
sensitivity and speciﬁcity, which sets the stage for building
an appropriate validation framework for IHC. As will be
shown technical validation is not possible in the absence
of analytical sensitivity and analytical speciﬁcity.20,21
Diagnostic and clinical sensitivity and speciﬁcity do not
apply to technical validation of IHC tests (even though a
valid methodology based on proper technical validation is
a fundamental requirement for clinical validation stud-
ies), but should be demonstrated/known before an IHC
test is introduced into clinical practice.22,23 Therefore,
they are also brieﬂy discussed below.
Analytical Sensitivity and Speciﬁcity
Generally speaking, analytical sensitivity represents
the smallest amount of substance in a sample that can
accurately be measured (for quantitative assays) or de-
tected (for qualitative assays) by an assay. In other words,
analytical sensitivity determines the limit of detection
(LOD).24,25 Analytical speciﬁcity refers to the ability of
an assay to uniquely measure or detect one particular
substance in a sample.26 It is critical to recognize that for
a descriptive method such as IHC, analytical sensitivity,
and analytical speciﬁcity are also descriptive. A pertinent
example is the demonstration of low molecular weight
cytokeratin (LMW-CK) in hepatocytes (a known weak
expressor of CK, thus suitable as a descriptive LOD cell
type). If an IHC test for LMW-CK shows positivity in
hepatocytes, then adequate analytical sensitivity has been
demonstrated.17 LMW-CK is not expressed in benign
TABLE 1. Test Performance Characteristic for Technical
Validation of Immunohistochemistry (IHC) Assays
Test Performance
Characteristic Deﬁnition
Analytical sensitivity Determines LOD* of an IHC test
Analytical speciﬁcity Ability of IHC assay to detect one particular
substance, rather than others
Preanalytical
reproducibility/
robustness
Ability of IHC assay to produce the same
results with the same tissue sample for
various preanalytical conditions
Analytical
reproducibility/
robustness
Ability of IHC assay to produce the same
results with the same tissue sample for
various analytical conditions
Readout accuracy Readout agreement with a designated gold
standard or designated true value for the
readout
Readout precision Readout reproducibility (intraobserver and
interobserver reproducibility of the
readout)
Reportable range Clinically relevant range of values that can be
described (or measured by image analysis)
for a certain antigen that can be detected by
IHC in specimens known to express the
antigen with a provision that the specimens
had undergone ideal/standard tissue
processing
EQA accuracy for
reportable range
Ability of IHC test to produce a correct result
in EQA (PT or interlaboratory), where
external IHC results act as the agreed upon
actual (true) value
NIM accuracy for
reportable range
Ability of IHC test to produce a correct result
in NIM (PT, interlaboratory, or
intralaboratory), where results of another
(previously validated) method (eg, FISH,
PCR, other) act as the agreed upon actual
(true) value
*Limit of detection (LOD); the smallest amount of substance in a sample that
can accurately be detected by an assay.
EQA, external quality assurance; FISH, ﬂuorescent in situ hybridization;
NIM, non-IHC method; PCR, polymerase chain reaction; PT, proﬁciency testing.
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lymphocytes, skeletal muscle, and many other tissues. If
an IHC test for LMW-CK is reproducibly negative in
known negative tissues, then adequate analytical speci-
ﬁcity has been demonstrated.27 In the clinical laboratory
analytical sensitivity and speciﬁcity are traditionally
determined against an analytical reference standard test
(ie, a criterion standard or colloquially, a “gold stand-
ard”), but this is currently not the norm in IHC testing
because for most IHC tests, gold standards are not yet
deﬁned. An Ad Hoc Expert Committee recently initiated
development of descriptive gold standards for descriptive
analytical sensitivity and speciﬁcity in IHC testing by
establishing the concept of standardized controls for IHC
tests, also referred to as IHC critical assay performance
controls (iCAPCs).17 Although iCAPCs include relevant
LOD tissue(s), analytical speciﬁcity is only narrowly ad-
dressed. To establish a more extended analytical speci-
ﬁcity it is desirable to include a spectrum of benign
human tissues in the evaluation of analytical speciﬁcity.
Such tissues may be combined into a so-called “speciﬁcity
tissue microarray (TMA)” (see part 4 of the Evolution
Series).
Diagnostic Sensitivity and Speciﬁcity
Diagnostic sensitivity is the probability that a test
outcome is positive in a diseased person (eg, for IHC tests
this usually relates to a particular type of tumor), and di-
agnostic speciﬁcity is the probability that a test outcome is
negative in a nondiseased person (eg, in a diﬀerent type of
tumor by IHC). In a clinical setting, 2 useful measures are
positive predictive value and negative predictive value.
Positive predictive value is deﬁned as the probability that a
person randomly chosen from the population who has
tested positive actually has the disease; negative predictive
value is the probability that a person who has tested neg-
ative does not have the disease. Clearly, these deﬁnitions
assume that the values are calculated and are relevant in
a deﬁned diagnostic setting.28 Therefore, if sensitivity and
speciﬁcity are deﬁned in these terms, we refer to
“diagnostic sensitivity and speciﬁcity”; this concept is
applicable to IHC in the setting of diagnosing a disease or
a condition. Diagnostic sensitivity and speciﬁcity of IHC
tests are often published in the pathology literature (eg,
sensitivity and speciﬁcity of DOG1 IHC assay in the
diagnosis of gastrointestinal stromal tumor).29–31
Clinical Sensitivity and Speciﬁcity
To establish clinical sensitivity and speciﬁcity (eg,
patient response to hormonal therapy for estrogen
receptor-positive breast cancer), clinical trials are neces-
sary; this requirement generally goes beyond the purview
of an individual laboratory.32,33
Clinical utility is a concept that incorporates both di-
agnostic and clinical sensitivity and speciﬁcity. Diagnostic
and clinical sensitivity and speciﬁcity may be known either
from studies performed by the laboratory itself, or those
reported in published literature or other reliable sources. For
example, studies that document diagnostic, prognostic, and
predictive relevance of IHC tests are frequently provided in
the peer-reviewed literature.34–39 IHC tests that have not
been diagnostically and clinically validated in published lit-
erature should not be introduced in a clinical IHC labo-
ratory without that laboratory itself performing a diagnostic
validation and/or clinical validation of its own. Tissue tools
for demonstration of IHC analytical sensitivity and speci-
ﬁcity are described in part 4 of the Evolution Series.
In summary, “clinical sensitivity and speciﬁcity”
relate to the ability of an IHC test to predict clinical
outcomes and clinical responses to therapeutic agents
(prognostic and predictive); “diagnostic sensitivity and
speciﬁcity” relate to the ability of an IHC test to diagnose
a disease or biological state; “analytical sensitivity and
speciﬁcity” relate to the ability of an IHC test to clearly
demonstrate signal in an agreed upon “LOD” cell type,
along with optimal signal-to-noise ratio in a ﬁt-for-pur-
pose manner.
Reproducibility and Robustness
Reproducibility and robustness were not speciﬁcally
addressed by the recent College of American Pathologists
guidelines for IHC validation.15 However, we would ar-
gue that because reproducibility is deﬁned as the ability of
a test to produce the same result for a given sample when
repeatedly tested, and robustness relates to test reprodu-
cibility given some changes in test conditions, both are
applicable to IHC validation.
Reproducibility Versus Precision
Reproducibility is the ability of a test to produce the
same results in repeat testing within a laboratory (it may
also be assessed across diﬀerent laboratories as discussed
below). It has been argued that reproducibility is to a
qualitative test what “precision” is to a quantitative
test.7,10,11,19,21,40 Therefore, for qualitative IHC assays,
the term “reproducibility” is preferred and the term
“precision” should not be used.
How to Measure Reproducibility?
Reproducibility is measured by the percentage of
times the same results are obtained when a test is per-
formed repeatedly on the same sample (specimen). Al-
though this approach to measuring reproducibility is
applicable to IHC testing, the phrase “the same results”
needs to be deﬁned for each test because IHC tests are
descriptive in nature (eg, for CD31 testing, demonstration
of strong staining of endothelial cells plus weak staining
of mantle zone lymphocytes in 9 of 10 slides from the
same paraﬃn block demonstrates 90% reproducibility).
Intralaboratory reproducibility for qualitative testing was
also recently referred to as “accordance.”41 The diﬀerence
between the usual understanding of intralaboratory re-
producibility and accordance is that reproducibility is
expressed as a percentage of the same set of results
(compared with a predeﬁned standard, such as control
materials), while accordance is measured by using paired
samples without a predeﬁned standard; it is a measure
(also in percentage) of how often the paired samples
produce the same results (positive vs. negative). Although
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reproducibility can be easily accessed by monitoring re-
sults of “on-slide standardized (or well deﬁned) controls”
daily, to assess accordance, we would need to prepare at
least 10 paired samples and compare their results for
agreement in a separate evaluation.
Which Samples to Use to Demonstrate
Reproducibility?
Proper selection of quality control samples is critical
for demonstration of reproducibility in a descriptive test
such as IHC, and such samples should optimally include
LOD tissues/cell types. Therefore, iCAPCs or similar
samples are well suited to be used for demonstration of
reproducibility of qualitative IHC assays (see part 4 of the
Evolution Series).
How Many Repeats of a Given Test are Necessary
to Demonstrate Reproducibility?
The number of repeat tests that is suﬃcient to dem-
onstrate reproducibility may be determined by regulatory
agencies, professional bodies, or by a laboratory medical
director. If standardized on-slide controls are used for IHC
testing, then the reproducibility of the test is continually
demonstrated and monitored with each IHC slide, because
the obtained results are regularly inspected at the intra-
laboratory QC stage of IHC testing. This approach is en-
dorsed because in clinical practice, slides that are deemed less
than optimal must be recognized, investigated (with
laboratory-initiated repeat testing if necessary), and properly
documented. Whether a laboratory-identiﬁed suboptimal
IHC slide is released to the pathologist who ordered the test
is usually the decision of the medical director of the labo-
ratory. A recent publication reported approximately 98%
overall reproducibility of the IHC tests in a single large
clinical laboratory.42
Robustness
The robustness of an IHC test (or other in situ cell-
based assays) is deﬁned as test reproducibility in the face
of changes in various test conditions.43,44 These changes
are often in preanalytical conditions, such as ﬁxation
time, decalciﬁcation, warm and cold ischemic time,
among others. Reproducibility of IHC results for a clin-
ically relevant range of preanalytical conditions deﬁnes
preanalytical robustness. Similarly, reproducibility of
IHC results for a clinically relevant range of analytical
conditions (eg, diﬀerent equipment, diﬀerent operators,
etc.) deﬁnes analytical robustness of the IHC test. Dem-
onstration of preanalytical robustness is under the pur-
view of the IHC laboratory, while analytical robustness is
the responsibility of both the laboratory and industry (eg,
manufacturers/suppliers of IHC reagents and equipment).
Many IHC laboratories do not establish robustness be-
cause robustness has not yet been mandated for IHC
validation and the number of tissue samples for estab-
lishing preanalytical or analytical robustness in IHC
validation has not yet been deﬁned. Tissue tools for
demonstration of IHC reproducibility and robustness are
described in part 4 of the Evolution Series.
Accuracy and Precision
Accuracy is usually deﬁned as the degree of close-
ness of a test measurement to the actual (true) or expected
(previously measured) value; this approach to accuracy is
not applicable to most IHC testing.43–45 Similar to pol-
ymerase chain reaction tests, IHC tests use ampliﬁcation
and are generally qualitative, and therefore cannot be
analyzed based on exact quantitative measurements; this
is in contrast to other, more quantitative methods that do
not use variable ampliﬁcation, where the output of the
test more closely reﬂects actual protein content/ex-
pression (eg, mass spectrometry, or even immunoassays
that use directly labelled primary antibody, such as mul-
ticolor ﬂow cytometry and direct immunoﬂuorescence).10
However, accuracy may be applicable to IHC testing in
deﬁned circumstances as follows: (1) accuracy of the IHC
protocol and (2) accuracy of the IHC readout.
(1) IHC protocol accuracy is sometimes inappropriately
referred to as “concordance.” “Concordance” has
also been considered as the equivalent of reproduci-
bility when measured across diﬀerent laboratories;
namely the percentage chance that 2 identical test
samples sent to diﬀerent laboratories will both yield
the same result (ie, both found positive or both found
negative result).41 However, in this context most of
the time one of the results is considered as the
designated gold standard result (designated “true
value”) and therefore, accuracy is a more appropriate
term because concordance reﬂects agreement of the
paired samples irrespective of the correctness of the
results. In clinical IHC, the output (“stained” slide) is
compared with a designated “gold standard,” where
the designated gold standard result (designated “true
value”) is provided by a reference laboratory (either
through interlaboratory exchange or through a
proﬁciency testing or PT program). In this context,
the IHC protocol accuracy is best referred to as
external quality assurance (EQA) accuracy.
Where the designated gold standard result (designated
“true value”) is determined using a non-IHC based
testing method, the IHC protocol accuracy is best
referred to as non-IHC methodology (NIM) accuracy.
In NIM accuracy, the ability of an IHC protocol to
produce a correct result is assessed in comparison
with another (non-IHC) test methodology for the
same biological condition (eg, comparison of IHC test
results with results obtained using ﬂuorescent in situ
hybridization or polymerase chain reaction testing).46
EQA accuracy may involve a reference laboratory
that provides both IHC and ﬂuorescent in situ
hybridization results for a set of PT samples while
testing for NIM accuracy may be performed by the
same laboratory performing the validation (intra-
laboratory NIM accuracy) or by an external labo-
ratory.
To assess IHC protocol accuracy, samples that
contain no analyte, as well as samples with low,
moderate, and high levels of analyte are usually
included. Professional organizations are likely to
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continue the practice of issuing recommendations
regarding the number of samples for intralaboratory
NIM accuracy, as well as the number of samples for
interlaboratory IHC exchanges and/or proﬁciency
testing that need to be included to enable meaningful
calculations.14,46–50 Although IHC protocol accuracy
is also often referred to as “concordance,” when
comparison is conducted with the agreed upon “true
value” of the IHC test, or with a designated “true
value” using another methodology, then “EQA
accuracy” and “NIM accuracy” are the preferred
terms. Concordance could be used when there is no
reference to “correct results,” but only interlaboratory
reproducibility is being assessed.
(2) There are many types of nonquantitative measure-
ments that are applicable to the IHC readout, which
produce diﬀerent types of data (eg, binary data,
categorical data, ordinal data, etc).10 Where accuracy
and precision apply only to the validation of the
readout as a speciﬁc segment of the IHC protocol,
they should be designated as “readout accuracy” and
“readout precision.” Readout accuracy refers to
readout agreement with a designated gold standard
or designated true value, and readout precision refers
to reproducibility of the readout per se (intraobserver
and interobserver reproducibility of the readout).
Readout accuracy and readout precision should be
determined for type 2-IHC tests (class II and class III
U.S. Food and Drug Administration IHC tests), and
for type 1-IHC tests (class I) where the read out
includes an element of quantiﬁcation (eg, % cells with
a deﬁned qualitative cutoﬀ point that distinguishes
between a “negative” and “positive” result). Note that
readout accuracy and readout precision are not the
same (eg, image analysis is expected to have very high
readout precision, but it may have very low readout
accuracy if an inappropriately calibrated algorithm is
used for the readout). The level of acceptability for
readout accuracy and readout precision of various
IHC tests may be set by regulatory bodies, profes-
sional organizations, or expert/subspecialty groups.
Readout accuracy and readout precision are partic-
ularly relevant for biomarkers that are used for
targeted therapy.32
Reportable Range
For liquid-based quantitative laboratory tests,
“analytical measurement range” is the term used by the
College of American Pathologists to refer to the range of
values that a quantitative method can measure for a sam-
ple, without dilution, concentration, or other pretreatment
of the specimen before testing. Analytical measurement
range is the same as “reportable range” in The Clinical
Laboratory Improvement Amendments terminology.51
When applied to IHC testing, which is a descriptive qual-
itative technique, the reportable range is usually considered
to be the clinically relevant range of results that can be
described (or measured by image analysis) for a given IHC
target that can be detected in specimens known to express
the antigen, with the provision that the specimens had
undergone ideal tissue processing (eg, ischemic time <1h,
overnight ﬁxation in formalin, and embedding in paraﬃn).
For example, a given range may extend from rare cells
positive, to all cells positive, etc. Depending on the IHC
protocol conditions, the intensity of staining, above a
threshold deﬁned in the controls, may or may not be rele-
vant. Examples include range of expression of estrogen
receptor in breast cancer, range of expression of CD10 in
follicular lymphoma, etc. Depending on the objective of the
test, 3 to 10 samples may be well representative of the re-
portable range. Reportable range samples may be com-
bined in the form of a TMA paraﬃn block (also known as
“Index TMA”; see part 4 of the Evolution Series). De-
pending on the type and the number of cases included,
accuracy TMA may also be suitable for demonstrating
reportable range for most IHC assays (see part 4 of the
Evolution Series).
Reportable range is also relevant for the
proper selection of quality control samples.17 Selection of
quality control samples for daily controls, and other quality
control samples must satisfy the minimum requirement of a
negative control and 2 positive controls containing diﬀerent
concentrations of the target antigen, to be included in every
run. Note that for modern automated IHC testing, each
slide in fact represents a separate run and, hence, the on-
slide control rule applies.17,42 The expression levels should
be chosen to verify assay performance for relevant analytic
and clinical decision points. This usually means including a
high-expressor positive control, near the upper limit of the
reportable range, as well as a low-expressor positive con-
trol, near or at the lower LOD.52
TPCs IN TEST VALIDATION
Demonstration of relevant TPCs is required for
technical IHC assay validation. In this discussion it is
assumed that primary antibodies and other reagents, as
well as equipment that will be used in clinical IHC testing,
have already been validated either by industry, or in
published literature. Therefore, clinical IHC laboratories
must perform additional technical validation of IHC
protocols. Furthermore, the medical director (or desig-
nate) of the clinical IHC laboratory is responsible for
validation of IHC readouts where applicable.
Technical validation of IHC testing is described in
detail in part 3 of Evolution Series.
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